Book a Demo

Sirnaomics

Home
/
Cases
/
Sirnaomics
Biotech Public Company
U.S. Bank Integration
Sirnaomics (Stock Code: 2257.HK) is an innovative biopharmaceutical company listed on the Main Board of the Hong Kong Stock Exchange, focused on the discovery and development of novel RNAi therapeutics for diseases with significant unmet medical needs. As a global leader in this field, the company has established key R&D centers and market presence in both China and the United States, and is committed to delivering breakthrough treatments to patients worldwide.
Project Introduction
RNAi therapy development requires strong group-level coordination of resources. This project establishes a multi-entity financial consolidation and R&D budget management platform, integrates U.S. banking and end-to-end supply chain processes, and enables refined expense control, accurate R&D cost tracking, and enhanced global operational efficiency.
Solutions
Multi-Entity Financial Consolidation R&D Project Management & Budget Control End-to-End Supply Chain Management U.S. Bank Integration End-to-End Expense Control
Project Benefits
Enhanced Group Financial Governance Improved Public Company Transparency Accurate R&D Cost Tracking Enhanced Global Operational Efficiency